Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant ...
If preclinical findings were translated into the clinic, they could shorten the CAR-T generation lead time from two weeks to ...
Roche outlined how digital health technologies (DHTs) provide more sensitive measures of disease progression in early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback